Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of ASP1617 in Healthy Volunteers
NCT04077879Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of asp1617 in systemic lupus erythematosus (SLE) (5 arms), sponsored by Astellas Pharma. Primary endpoints: Number of participants with adverse events (AEs) in Part 1, Number of participants with laboratory value abnormalities and/or AEs in Part 1 and 1 more. Started Sep 2019; status: completed.
02
Drugs
asp1617
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04077879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04077879.